Preprint Article Version 2 Preserved in Portico This version is not peer-reviewed

Assessing the Impact of Hemodynamic Monitoring with CardioMEMS on Heart Failure Patients: A Cost-Benefit Analysis

Version 1 : Received: 3 January 2023 / Approved: 6 January 2023 / Online: 6 January 2023 (04:41:21 CET)
Version 2 : Received: 17 September 2023 / Approved: 18 September 2023 / Online: 19 September 2023 (05:23:15 CEST)

How to cite: Codina, P.; Vicente Gómez, J.A.; Hernández Guillamet, G.; Ricou Ríos, L.; Carrete, A.; Vilalta, V.; Estrada, O.; Ara, J.; Lupón, J.; Bayés-Genís, A.; López Seguí, F. Assessing the Impact of Hemodynamic Monitoring with CardioMEMS on Heart Failure Patients: A Cost-Benefit Analysis. Preprints 2023, 2023010116. https://doi.org/10.20944/preprints202301.0116.v2 Codina, P.; Vicente Gómez, J.A.; Hernández Guillamet, G.; Ricou Ríos, L.; Carrete, A.; Vilalta, V.; Estrada, O.; Ara, J.; Lupón, J.; Bayés-Genís, A.; López Seguí, F. Assessing the Impact of Hemodynamic Monitoring with CardioMEMS on Heart Failure Patients: A Cost-Benefit Analysis. Preprints 2023, 2023010116. https://doi.org/10.20944/preprints202301.0116.v2

Abstract

Aims: The objective of this study was to assess the cost-effectiveness of the CardioMEMS HF system in a HF Clinic in Spain by evaluating the real-time remote monitoring of pulmonary artery pressures, which has shown to reduce heart failure (HF) related hospitalizations and improve the quality of life for selected HF patients. Particularly, the study aimed to determine the value of CardioMEMS in Southern Europe, where healthcare costs are significantly lower and its effectiveness remains uncertain. Methods: This single-centre study enrolled all consecutive HF patients who had been implanted with a pulmonary artery pressure sensor (CardioMEMS-HF system, Abbott Laboratories, Abbott Park, IL, USA). The number of HF hospitalizations in the year before and the year after the sensor implantation was compared and quality-adjusted life years (QALY) gained based on a literature review of previous studies was calculated. Results: The rate of HF hospitalisations was significantly lower at 1 year compared with the year before CardioMEMS implantation (0.25 versus 1.10 events/patient-years, HR 0.22, p=0.001). At the end of first year, the usual management outperformed the CardioMEMS HF system, resulting in a net monetary value difference of 2,540€ per patient and a benefit-cost ratio of 0.38. However, by the end of the second year, the CardioMEMS system is estimated to reduce costs compared to usual management. Conclusions: Based on the results, we suggest that remote monitoring of pulmonary artery pressure with the CardioMEMS HF system represents a long-term cost-effective strategy in a healthcare setting in Southern Europe.

Keywords

cost-effectiveness evaluation; heart failure; telemonitoring; pulmonary artery pressure; hemodynamic monitoring

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (1)

Comment 1
Received: 19 September 2023
Commenter: Jose Angel Vicente Gómez
Commenter's Conflict of Interests: Author
Comment: Changes in methodology: from cost-effectiveness to cost-benefit, changes in the control population
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.